NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
4.72
Dollar change
-0.06
Percentage change
-1.26
%
IndexRUT P/E- EPS (ttm)-0.76 Insider Own6.87% Shs Outstand58.93M Perf Week5.59%
Market Cap278.17M Forward P/E- EPS next Y-0.39 Insider Trans2.40% Shs Float54.89M Perf Month7.52%
Enterprise Value-51.00M PEG- EPS next Q-0.36 Inst Own75.79% Short Float8.61% Perf Quarter0.64%
Income-44.25M P/S1.38 EPS this Y-352.53% Inst Trans2.01% Short Ratio8.77 Perf Half Y-2.28%
Sales201.35M P/B0.54 EPS next Y74.11% ROA-6.89% Short Interest4.73M Perf YTD-1.46%
Book/sh8.68 P/C0.82 EPS next 5Y55.04% ROE-8.38% 52W High6.36 -25.84% Perf Year-21.07%
Cash/sh5.78 P/FCF- EPS past 3/5Y- - ROIC-8.53% 52W Low3.81 23.91% Perf 3Y-56.17%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-9.56% -2.64% Gross Margin90.86% Volatility4.09% 3.42% Perf 5Y-60.30%
Dividend TTM- EV/Sales-0.25 EPS Y/Y TTM-793.98% Oper. Margin-35.98% ATR (14)0.16 Perf 10Y-63.64%
Dividend Ex-Date- Quick Ratio3.91 Sales Y/Y TTM13.37% Profit Margin-21.98% RSI (14)59.65 Recom1.67
Dividend Gr. 3/5Y- - Current Ratio3.93 EPS Q/Q-601.81% SMA203.61% Beta0.68 Target Price12.67
Payout- Debt/Eq0.02 Sales Q/Q5.43% SMA507.36% Rel Volume0.69 Prev Close4.78
Employees368 LT Debt/Eq0.01 EarningsMay 07 AMC SMA2001.95% Avg Volume539.10K Price4.72
IPOApr 12, 2006 Option/ShortYes / Yes EPS/Sales Surpr.12.79% 10.87% Trades Volume375,218 Change-1.26%
Date Action Analyst Rating Change Price Target Change
Oct-31-24Initiated H.C. Wainwright Buy $18
Jul-11-24Initiated Cantor Fitzgerald Overweight $11
Feb-25-22Downgrade Jefferies Buy → Hold $24 → $12
May-12-21Initiated BofA Securities Buy $22
Jan-14-21Downgrade Citigroup Buy → Neutral $14
Oct-29-20Upgrade Citigroup Neutral → Buy $14
Jun-09-20Downgrade Citigroup Buy → Neutral $14
Mar-16-20Downgrade Oppenheimer Perform → Underperform
Mar-12-20Upgrade Citigroup Neutral → Buy $14
Nov-07-19Downgrade Citigroup Buy → Neutral $19
Jun-10-25 08:00AM
May-27-25 09:00AM
May-16-25 05:30PM
May-08-25 08:04AM
03:28AM
07:56PM Loading…
May-07-25 07:56PM
07:55PM
05:10PM
04:07PM
04:01PM
May-05-25 08:00AM
May-02-25 08:46AM
May-01-25 05:35PM
Apr-28-25 04:00AM
Apr-25-25 06:34AM
03:52PM Loading…
Apr-23-25 03:52PM
Apr-07-25 02:21PM
08:00AM
Mar-31-25 08:00AM
Feb-24-25 07:00AM
Feb-14-25 09:41AM
02:20AM
Feb-13-25 05:15PM
04:18PM
04:01PM
Feb-05-25 04:30PM
Feb-04-25 06:37AM
Feb-03-25 07:30AM
Jan-29-25 05:39AM
Jan-27-25 07:00AM
01:47PM Loading…
Jan-16-25 01:47PM
Jan-08-25 04:17PM
Dec-20-24 09:13AM
Nov-12-24 04:58PM
Nov-07-24 02:21AM
Nov-06-24 04:12PM
04:02PM
Nov-01-24 02:05PM
Oct-31-24 12:27PM
Oct-30-24 04:30PM
Oct-15-24 08:30AM
Oct-14-24 12:08PM
10:56AM
10:37AM
08:19AM
Sep-20-24 07:28AM
06:12AM
Sep-19-24 05:20PM
07:00AM
Sep-11-24 05:00PM
Sep-04-24 05:13PM
Aug-29-24 04:30PM
Aug-01-24 08:49AM
Jul-31-24 04:06PM
04:01PM
Jul-26-24 09:19AM
Jul-01-24 08:01AM
Jun-28-24 06:53AM
Jun-21-24 07:00AM
Jun-19-24 08:48PM
Jun-13-24 09:00PM
10:02AM
Jun-07-24 06:02AM
Jun-06-24 09:24AM
08:00AM
07:38AM
May-30-24 05:20PM
04:48PM
May-29-24 02:17PM
May-24-24 04:46PM
May-16-24 11:24AM
06:22AM
May-15-24 01:04PM
08:45AM
May-10-24 03:24PM
May-09-24 12:37PM
06:43AM
03:38AM
May-08-24 08:58PM
04:10PM
04:01PM
May-07-24 11:33AM
11:16AM
09:22AM
09:10AM
09:00AM
Apr-30-24 04:30PM
Apr-25-24 10:45AM
09:00AM
08:05AM
Apr-24-24 06:00PM
01:58PM
Apr-22-24 07:13PM
04:11PM
11:37AM
10:09AM
Apr-19-24 01:06PM
Apr-18-24 09:44AM
09:00AM
Apr-17-24 02:29PM
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mitchell Stephen RayDirectorJun 13 '25Sale4.597,00032,13097,082Jun 16 09:10 PM
Mitchell Stephen RayDirectorJun 13 '25Proposed Sale4.597,00032,159Jun 13 09:40 PM
Polymeropoulos Mihael HristosPresident and CEOMay 21 '25Buy4.4010,00043,9952,325,731May 21 09:23 PM
Polymeropoulos Mihael HristosPresident and CEOMay 16 '25Buy4.2220,00084,4722,315,731May 19 05:13 PM
Polymeropoulos Mihael HristosPresident and CEOMar 06 '25Buy5.0110,00050,1502,295,731Mar 06 05:53 PM
Polymeropoulos Mihael HristosPresident and CEOMar 05 '25Buy5.0210,00050,2002,285,731Mar 05 05:19 PM
Polymeropoulos Mihael HristosPresident and CEOMar 03 '25Buy4.7110,00047,0502,275,731Mar 04 04:45 PM
Polymeropoulos Mihael HristosPresident and CEOFeb 28 '25Buy4.7610,00047,6002,361,730Feb 28 05:30 PM
Polymeropoulos Mihael HristosPresident and CEOFeb 27 '25Buy4.7610,00047,6002,351,730Feb 27 04:13 PM
Polymeropoulos Mihael HristosPresident and CEOFeb 26 '25Buy4.7610,00047,6502,341,730Feb 26 04:46 PM
Polymeropoulos Mihael HristosPresident and CEOFeb 25 '25Buy4.4610,00044,6402,331,730Feb 25 07:38 PM
Moran Kevin PatrickSVP, CFO & TreasurerFeb 21 '25Buy4.392,0008,779355,763Feb 24 07:04 PM
Mitchell Stephen RayDirectorNov 14 '24Sale5.175,00025,86344,857Nov 18 05:45 PM
Mitchell Stephen RayDirectorNov 14 '24Proposed Sale5.405,00027,000Nov 14 04:10 PM
Moran Kevin PatrickSVP, CFO & TreasurerJul 29 '24Sale5.922,25113,327228,763Jul 29 05:24 PM
Moran Kevin PatrickOfficerJul 29 '24Proposed Sale5.922,25113,327Jul 29 05:21 PM